<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02525549</url>
  </required_header>
  <id_info>
    <org_study_id>PRG-817</org_study_id>
    <nct_id>NCT02525549</nct_id>
  </id_info>
  <brief_title>Comparative Safety and Bioequivalence of Two Treatments in the Treatment of Acne Vulgaris</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Padagis LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Padagis LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the safety and bioequivalence of Perrigo's product to&#xD;
      an FDA approved product for the treatment acne vulgaris.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2011</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Percent Change From Baseline to Day 84 in Inflammatory (Papules and Pustules) Lesions</measure>
    <time_frame>84 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Percent Change From Baseline to Day 84 in Non-inflammatory (Open and Closed Comedones) Lesions</measure>
    <time_frame>84 days</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">903</enrollment>
  <condition>Acne</condition>
  <arm_group>
    <arm_group_label>Test product</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adapalene and Benzoyl Peroxide Gel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reference product</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Adapalene and Benzoyl Peroxide Gel (Reference)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo product</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo gel</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adapalene and Benzoyl Peroxide Gel</intervention_name>
    <arm_group_label>Test product</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adapalene and Benzoyl Peroxide Gel (Reference)</intervention_name>
    <arm_group_label>Reference product</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo gel</intervention_name>
    <arm_group_label>Placebo product</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and non-pregnant female subjects, 12 to 40 years of age (inclusive), with a&#xD;
             clinical diagnosis of at least moderate facial acne vulgaris&#xD;
&#xD;
          -  Inflammatory lesion (papules and pustules) count of 20 to 50 (inclusive)&#xD;
&#xD;
          -  Non-inflammatory (open and closed comedones) lesion count of 25 to 100 (inclusive)&#xD;
&#xD;
          -  No more than two nodulocystic lesions (i.e., nodules and cysts) on the face including&#xD;
             those present on the nose, were enrolled.&#xD;
&#xD;
          -  Subjects must also have had a Baseline IGA score of 3 or 4 on a severity scale of 0 to&#xD;
             4 to be enrolled.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects who are pregnant, nursing, or planning a pregnancy within the study&#xD;
             participation period.&#xD;
&#xD;
          -  Presence of more than 2 facial Nodulocystic lesions (i.e. nodules and cysts)&#xD;
&#xD;
          -  Subjects with active cystic acne or Polycystic Ovarian Syndrome&#xD;
&#xD;
          -  Presence of any other facial skin condition that, in the Investigator's opinion, might&#xD;
             interfere with acne vulgaris diagnosis and/or evaluations (e .g., on the face:&#xD;
             rosacea, dermatitis, psoriasis, squamous cell carcinoma, eczema, acneform eruptions&#xD;
             caused by medications, steroid acne, steroid folliculitis, or bacterial folliculiti&#xD;
             s).&#xD;
&#xD;
          -  Excessive facial hair (e.g. beards, sideburns, moustaches, etc.) that would interfere&#xD;
             with diagnosis or assessment of acne vulgaris.&#xD;
&#xD;
          -  Acne conglobata, acne fulminan s, or secondary acne (chloracne, drug-induced acne,&#xD;
             etc.)&#xD;
&#xD;
          -  Use of antipruritics including antihistamine, within 24 hours prior to all study&#xD;
             visits (Visit l/Baseline through Visit 4).&#xD;
&#xD;
          -  Use of medicated make-up throughout the study and significant change in the use of&#xD;
             consumer products within 30 days of study entry and throughout the study (other than&#xD;
             study supplied cleanser and lotion).&#xD;
&#xD;
          -  Use within 6 months prior to baseline or during the study of oral retinoids (e.g.&#xD;
             Accutane&quot;') or therapeutic vitamin A supplements of greater than 10,000 units/day&#xD;
             (multivitamins are allowed).&#xD;
&#xD;
          -  Use within 1 month prior to baseline or during the study of therapeutic vitamin D&#xD;
             supplement (multivitamins are allowed).&#xD;
&#xD;
          -  Use within 1 month prior to baseline or during the study of 1) systemic sterOids', 2)&#xD;
             systemic antibiotics, 3) systemic treatment for acne vulgaris (other than oral&#xD;
             retinoids which require a 6-month washout), or 4) systemic anti-inflammatory agents&quot;.&#xD;
             (' Intranasal and inhaled corticosteroids do not require a washout and may be used&#xD;
             throughout the study if at a stable and standard dose. &quot;Subjects may use Acetaminophen&#xD;
             for pain relief, as needed, throughout the study)&#xD;
&#xD;
          -  Use within 14 days prior to baseline or during the study of 1) topical sterOids, 2)&#xD;
             topical retinoids, 3) topical acne treatments including over-the-counter preparation&#xD;
             (e.g. azelaic acid,etc.) 4)a-hydroxy/glycolic acid, 5) benzoyl peroxide, 6) topical&#xD;
             anti-inflammatory agents, or 7) topical antibiotics.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 14, 2015</study_first_submitted>
  <study_first_submitted_qc>August 14, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 17, 2015</study_first_posted>
  <results_first_submitted>November 23, 2020</results_first_submitted>
  <results_first_submitted_qc>December 28, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">January 20, 2021</results_first_posted>
  <disposition_first_submitted>August 17, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>August 17, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">September 3, 2015</disposition_first_posted>
  <last_update_submitted>October 29, 2021</last_update_submitted>
  <last_update_submitted_qc>October 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adapalene</mesh_term>
    <mesh_term>Benzoyl Peroxide</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>October 1, 2012</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/49/NCT02525549/Prot_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 1, 2012</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/49/NCT02525549/SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Test Product</title>
          <description>Adapalene and Benzoyl Peroxide Gel&#xD;
Adapalene and Benzoyl Peroxide Gel</description>
        </group>
        <group group_id="P2">
          <title>Reference Product</title>
          <description>Adapalene and Benzoyl Peroxide Gel (Reference)&#xD;
Adapalene and Benzoyl Peroxide Gel (Reference)</description>
        </group>
        <group group_id="P3">
          <title>Placebo Product</title>
          <description>Placebo gel&#xD;
Placebo gel</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="365"/>
                <participants group_id="P2" count="360"/>
                <participants group_id="P3" count="178"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="330"/>
                <participants group_id="P2" count="307"/>
                <participants group_id="P3" count="159"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="53"/>
                <participants group_id="P3" count="19"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Test Product</title>
          <description>Adapalene and Benzoyl Peroxide Gel&#xD;
Adapalene and Benzoyl Peroxide Gel</description>
        </group>
        <group group_id="B2">
          <title>Reference Product</title>
          <description>Adapalene and Benzoyl Peroxide Gel (Reference)&#xD;
Adapalene and Benzoyl Peroxide Gel (Reference)</description>
        </group>
        <group group_id="B3">
          <title>Placebo Product</title>
          <description>Placebo gel&#xD;
Placebo gel</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="365"/>
            <count group_id="B2" value="360"/>
            <count group_id="B3" value="178"/>
            <count group_id="B4" value="903"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19.9" spread="6.25"/>
                    <measurement group_id="B2" value="20.4" spread="6.96"/>
                    <measurement group_id="B3" value="19.5" spread="6.55"/>
                    <measurement group_id="B4" value="20.0" spread="6.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="199"/>
                    <measurement group_id="B2" value="213"/>
                    <measurement group_id="B3" value="103"/>
                    <measurement group_id="B4" value="515"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="166"/>
                    <measurement group_id="B2" value="147"/>
                    <measurement group_id="B3" value="75"/>
                    <measurement group_id="B4" value="388"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="70"/>
                    <measurement group_id="B2" value="59"/>
                    <measurement group_id="B3" value="27"/>
                    <measurement group_id="B4" value="156"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="295"/>
                    <measurement group_id="B2" value="301"/>
                    <measurement group_id="B3" value="151"/>
                    <measurement group_id="B4" value="747"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="43"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="73"/>
                    <measurement group_id="B2" value="87"/>
                    <measurement group_id="B3" value="34"/>
                    <measurement group_id="B4" value="194"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="259"/>
                    <measurement group_id="B2" value="245"/>
                    <measurement group_id="B3" value="132"/>
                    <measurement group_id="B4" value="636"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Percent Change From Baseline to Day 84 in Inflammatory (Papules and Pustules) Lesions</title>
        <time_frame>84 days</time_frame>
        <population>Per protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>Test Product</title>
            <description>Adapalene and Benzoyl Peroxide Gel&#xD;
Adapalene and Benzoyl Peroxide Gel</description>
          </group>
          <group group_id="O2">
            <title>Reference Product</title>
            <description>Adapalene and Benzoyl Peroxide Gel (Reference)&#xD;
Adapalene and Benzoyl Peroxide Gel (Reference)</description>
          </group>
          <group group_id="O3">
            <title>Placebo Product</title>
            <description>Placebo gel&#xD;
Placebo gel</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Percent Change From Baseline to Day 84 in Inflammatory (Papules and Pustules) Lesions</title>
          <population>Per protocol population</population>
          <units>percent change of lesion counts</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="268"/>
                <count group_id="O2" value="247"/>
                <count group_id="O3" value="134"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.07" spread="36.6"/>
                    <measurement group_id="O2" value="65.58" spread="28.42"/>
                    <measurement group_id="O3" value="41.63" spread="28.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>provides 85% power of success</non_inferiority_desc>
            <param_type>Equivalence ratio</param_type>
            <param_value>93.12</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>88.6</ci_lower_limit>
            <ci_upper_limit>102.00</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Percent Change From Baseline to Day 84 in Non-inflammatory (Open and Closed Comedones) Lesions</title>
        <time_frame>84 days</time_frame>
        <population>Per protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>Test Product</title>
            <description>Adapalene and Benzoyl Peroxide Gel&#xD;
Adapalene and Benzoyl Peroxide Gel</description>
          </group>
          <group group_id="O2">
            <title>Reference Product</title>
            <description>Adapalene and Benzoyl Peroxide Gel (Reference)&#xD;
Adapalene and Benzoyl Peroxide Gel (Reference)</description>
          </group>
          <group group_id="O3">
            <title>Placebo Product</title>
            <description>Placebo gel&#xD;
Placebo gel</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Percent Change From Baseline to Day 84 in Non-inflammatory (Open and Closed Comedones) Lesions</title>
          <population>Per protocol population</population>
          <units>percent change of lesion counts</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="268"/>
                <count group_id="O2" value="247"/>
                <count group_id="O3" value="134"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.33" spread="32.00"/>
                    <measurement group_id="O2" value="55.06" spread="32.62"/>
                    <measurement group_id="O3" value="36.40" spread="38.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>provides 85% power of success</non_inferiority_desc>
            <param_type>Equivalence ratio</param_type>
            <param_value>98.7</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>92.3</ci_lower_limit>
            <ci_upper_limit>109.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>84 Days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Test Product</title>
          <description>Adapalene and Benzoyl Peroxide Gel&#xD;
Adapalene and Benzoyl Peroxide Gel</description>
        </group>
        <group group_id="E2">
          <title>Reference Product</title>
          <description>Adapalene and Benzoyl Peroxide Gel (Reference)&#xD;
Adapalene and Benzoyl Peroxide Gel (Reference)</description>
        </group>
        <group group_id="E3">
          <title>Placebo Product</title>
          <description>Placebo gel&#xD;
Placebo gel</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="365"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="365"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="360"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="365"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="178"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="365"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="365"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="360"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion Spontaneous</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="365"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="365"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="360"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="178"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jonathan Schwartz</name_or_title>
      <organization>Perrigo</organization>
      <phone>718-960-9900</phone>
      <email>jonathan.schwartz@perrigo.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

